JOHN KIRKWOOD to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Antineoplastic Agents, Immunological.
Connection Strength
3.514
-
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76?K trial. Eur J Cancer. 2025 May 02; 220:115371.
Score: 0.860
-
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020 02 20; 38(6):567-575.
Score: 0.599
-
Neoadjuvant ipilimumab (3?mg/kg or 10?mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018 10 23; 6(1):112.
Score: 0.552
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025 May 02; 220:115381.
Score: 0.215
-
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 May 10; 42(14):1619-1624.
Score: 0.200
-
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 03 02; 388(9):813-823.
Score: 0.187
-
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021 02 05; 371(6529):595-602.
Score: 0.162
-
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.
Score: 0.150
-
Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer. 2019 09 04; 7(1):239.
Score: 0.146
-
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44.
Score: 0.134
-
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018 05 14; 6(1):35.
Score: 0.134
-
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
Score: 0.132
-
Adjuvant Pembrolizumab versus IFNa2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discov. 2022 03 01; 12(3):644-653.
Score: 0.044